When combined with gemcitabine, EGCG suppressed tumor migration and invasion by downregulating the zinc finger E-box binding homeobox 1 (ZEB1), β-Catenin, and vimentin pathways, while inhibiting Akt and EMT pathways [125]. The gene discussed is VIM; the disease is neoplasm.